Drugs to Watch report: 15 blockbusters for 2023

Clarivate study highlights treatments with blockbuster potential | IV, Parkinson’s disease, Crohn’s disease, alopecia, multiple myeloma and breast cancer make the list | Nine blockbusters from China also predicted.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Sanofi launches mRNA lawsuits on Moderna and Pfizer

15 July 2026 French drugmaker's Translate Bio unit accuses COVID rivals of infringing core lipid nanoparticle and mRNA purification patents, seeking damages from vaccines worth billions.

Pharma

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

14 July 2026 An enhanced agreement between the two countries cements existing protections for pharma innovators and is being hailed by the industry as a boost for investment and research.

Pharma

Influential Women in IP 2026: Who made the list?

7 July 2026 Leading women from the pharmaceutical and biotechnology sectors are among the more than 100 professionals recognised in a newly released Influential Women in IP 2026 list, which celebrates leadership, expertise and innovation.

More features

Sanofi launches mRNA lawsuits on Moderna and Pfizer

UK-Switzerland strike trade deal with first-of-its-kind pharma rules

IP Federation elects Philips licensing leader as new president

Interview: How BlueRock Therapeutics is layering IP in stem cell therapies

Explaining genetically engineered rodents to a jury—and ultimately beating Amgen

Exelixis opens two-front patent dispute over Cabometyx copies

UPC upholds injunction in Invisalign maker’s software dispute with rival

BioNTech and Pfizer secure big European win over mRNA patent

Drugs to Watch report: 15 blockbusters for 2023

More on this story

Editor's picks

Editor's picks

More features